ZSP1601

Experimental drug

This article is an orphan, as no other articles link to it . Please introduce links to this page from related articles . (December 2023)

Pharmaceutical compound

ZSP1601
Legal status

Legal status	Investigational
Identifiers
IUPAC name 7-(Cyclopropylmethyl)-3,7-dihydro-1-[(cis-4-hydroxy-4-methylcyclohexyl)methyl]-3-methyl-1H-purine-2,6-dione
CAS Number	1900710-71-5
Chemical and physical data
Formula	C₁₈H₂₆N₄O₃
Molar mass	346.431g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C(N1C2=C(N(C)C(=O)N(C[C@@H]3CC[C@](C)(O)CC3)C2=O)N=C1)C4CC4

ZSP1601 is an experimental pan-phosphodiesterase inhibitor developed by Guangdong Raynovent Biotech for nonalcoholic steatohepatitis.^[1]^[2]

References

↑ Zhu, Xiaoxue; Wu, Min; Wang, Hong; Li, Haijun; Lin, Junjie; Peng, Yun; Hu, Yue; Li, Cuiyun; Ding, Yanhua (4 May 2021). "Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study". Expert Opinion on Investigational Drugs. 30 (5): 579–589. doi:10.1080/13543784.2021.1900822. PMID 33682556. S2CID 232140574.
↑ Hu, Yue; Li, Haijun; Zhang, Hong; Chen, Xiaoxin; Chen, Jinjun; Xu, Zhongyuan; You, Hong; Dong, Ruihua; Peng, Yun; Li, Jing; Li, Xiaojiao; Wu, Dandan; Zhang, Lei; Cao, Di; Jin, He; Qiu, Dongdong; Yang, Aruhan; Lou, Jinfeng; Zhu, Xiaoxue; Niu, Junqi; Ding, Yanhua (12 October 2023). "ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial". Nature Communications. 14 (1): 6409. Bibcode:2023NatCo..14.6409H. doi:10.1038/s41467-023-42162-0 . ISSN 2041-1723. PMC 10570369 . PMID 37828034.